Risk of hospitalization in a sample of COVID-19 patients with and without chronic obstructive pulmonary disease

Myers, Laura C.; Murray, Richard; Donato, Bonnie M K; Vincent, Jean‐Louis; Kipnis, Patricia; Shaikh, Asif; Franchino‐Elder, Jessica

doi:10.1016/j.rmed.2022.107064

Cited by 3 publications

(2 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies reported a major impact on melanoma cancer due to diminished screening because of COVID-19. The chronic obstructive pulmonary disease was more severe among patients diagnosed with COVID-19 compared with patients who were not diagnosed with COVID-19 [ 23 ].…”

Section: Introductionmentioning

confidence: 99%

The effect of COVID-19 on cancer incidences in the U.S

Shanmugam,

Fulton,

Kruse

et al. 2024

Heliyon

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

The effect of COVID-19 on cancer incidences in the U.S

Shanmugam,

Fulton,

Kruse

et al. 2024

Heliyon

View full text Add to dashboard Cite

“…Asthma generally has not been associated with worse COVID-19 outcomes ( 1 – 5 ), except severe asthma may increase risk for hospitalizations, critical illness, and death in some reports ( 6 ). COPD has been more consistently associated with increased risk of mortality in those with COVID-19 ( 3 , 5 , 7 , 8 ), but not all studies have found an association with mortality in fully adjusted models ( 1 , 9 , 10 ).…”

mentioning

confidence: 95%

COVID-19 Severity and Mortality in Veterans with Chronic Lung Disease

Crothers,

Adams,

Turner

et al. 2024

Annals ATS

View full text Add to dashboard Cite

Rationale Chronic lung diseases (CLDs) have been variably associated with a risk for more severe manifestations and death with coronavirus disease (COVID-19). Objectives To determine the risk overall and by type of CLD for severity of COVID-19 outcomes in a U.S. national cohort. Methods Using data from the Veterans Health Administration, we determined the risk associated with CLDs, including chronic obstructive pulmonary disease (COPD) (mild or severe), asthma (mild, active, or severe), idiopathic pulmonary fibrosis (IPF), sarcoidosis, and other interstitial lung diseases (ILDs) for outcomes among veterans with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-positive tests between March 1, 2020 and April 30, 2021. We used multinomial regression to estimate risk of four mutually exclusive COVID-19 outcomes within 30 days: outpatient management, hospitalization, hospitalization with indicators of critical illness, or death. We calculated the overall proportion with each outcome, the absolute risk difference, and risk ratios for each outcome between those with and without CLD. We also describe clinical and laboratory abnormalities by CLD in those hospitalized. Results We included 208,283 veterans with COVID-19; 35,587 (17%) had CLD. Compared with no CLD, veterans with CLD were older and had more comorbidities. Hospitalized veterans with CLD were more likely to have low temperature, mean arterial pressure, oxygen saturation, and leukopenia and thrombocytopenia and were more likely to receive oxygen, mechanical ventilation, and vasopressors. Veterans with CLD were significantly less likely to have mild COVID-19 (−4.5%; adjusted risk ratio [aRR], 0.94; 95% confidence interval [CI], 0.94–0.95), and more likely to have a moderate (+2.5%; aRR, 1.21; 95% CI, 1.18–1.24), critical (+1.4%; aRR, 1.38; 95% CI, 1.32–1.45), or fatal (+0.7%; aRR, 1.15; 95% CI, 1.10–1.20) outcome. IPF was most strongly associated with COVID-19 severity, especially mortality (+3.2%; aRR, 1.69; 95% CI, 1.46–1.96), followed by other ILDs and COPD, whereas asthma was less likely to be associated with severity of COVID-19. In veterans younger than age 65 years, worse COVID-19 outcomes were generally more likely with IPF, sarcoidosis, and other ILDs. Conclusions Veterans who had CLD, particularly IPF, other ILDs, and COPD, had an increased probability of more severe 30-day outcomes with COVID-19. These results provide insight into the absolute and relative risk of different CLDs with severity of COVID-19 outcomes and can help inform considerations of healthcare utilization and prognosis. Observational clinical epidemiology study registered with www.clinicaltrials.gov (NCT04628039).

show abstract

The Research Progress and Consideration on the Influence of Respiratory Infectious Dis-eases on COPD Patients Were Reviewed from the Clinical Perspective

程

2023

ACM

View full text Add to dashboard Cite

Risk of hospitalization in a sample of COVID-19 patients with and without chronic obstructive pulmonary disease

Cited by 3 publications

References 63 publications

The effect of COVID-19 on cancer incidences in the U.S

The effect of COVID-19 on cancer incidences in the U.S

COVID-19 Severity and Mortality in Veterans with Chronic Lung Disease

The Research Progress and Consideration on the Influence of Respiratory Infectious Dis-eases on COPD Patients Were Reviewed from the Clinical Perspective

Contact Info

Product

Resources

About